UNSPSC 51291504: Cimoxatone

This classification denotes a monoamine oxidase inhibitor with the molecular formula C19H18N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6FT1QJ7VL, chemically known as benzonitrile, 3-((4-(5-(methoxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)methyl)- but generally known as cimoxatone, which bears US NIH Compound Identifier 52542. European Medicines Agency schedules Cimoxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06281MIG.

UNSPSC 51291504 Cimoxatone (Commodity) does not align with recent state and local procurement activity under this code. The three most recent opportunities posted show minimal to no connection to cimoxatone itself — a pharmaceutical compound used in psychiatric treatment — and instead reflect solicitation of naloxone (opioid antagonist), safe drug deactivation systems, and generic multi-source pharmaceuticals through cooperative purchasing agreements and direct-to-manufacturer pharmacy initiatives. The code appears to receive little relevant recent activity, and the mismatch between the code's nominal scope and actual procurement suggests either a cataloging error in how opportunities were tagged or extremely limited use of this specific Commodity code in state and local purchasing.

The single concrete opportunity directly mentioning this code tier is Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023), which procures naloxone and drug deactivation systems rather than cimoxatone. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products through three authorized wholesalers, and the Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) exploring direct-to-manufacturer prescription programs. None of these solicitations target cimoxatone specifically. Business development professionals should verify whether activity under this code warrants pursuit, as the taxonomy classification does not reflect the pharmaceutical commodity categories state and local buyers are actively soliciting.